Jim Cramer likes Xilinx and Abbott Labs, but he's bearish on Xerox and Huntsman.
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
Doug Kass shares his thoughts on the market, and offers up some especially deep thoughts.
Carl Icahn exited his positions in Allergan and Nuance Communications during the first quarter of the year and acquired a stake in a Xerox spinoff after pressuring for a split.